Adaptive Biotechnologies at Goldman Sachs Conference: Strong Q1 Performance and Strategic Growth

Adaptive Biotechnologies' CEO Chad Robbins presented at the Goldman Sachs Healthcare Conference, highlighting a record-breaking Q1 driven by a 30% increase in MRD testing volume growth and a $4.5 million milestone payment from pharma partnerships. The company is focused on expanding its market presence through partnerships like the one with NeoGenomics (projected to boost testing volumes by 26-27%) and transitioning pharma contracts to a fee-for-service model to mitigate milestone delays, with gross margins projected to exceed 70% and EBITDA margins above 20%. Adaptive is also implementing operational improvements, such as transitioning to NovaSeq X instruments, expected to enhance margins by 5-8% over the next year, and targeting higher ASPs through updated payer contracts, aiming for $1,700-$1,800.

Analysis

Adaptive Biotechnologies (NASDAQ:ADPT) presented a robust outlook at the Goldman Sachs 46th Annual Global Healthcare Conference, underpinned by a record-breaking first quarter performance in its Minimal Residual Disease (MRD) testing segment. CEO Chad Robbins reported significant Q1 achievements, including a 30% year-over-year increase in MRD clinical volume growth, strong average selling prices (ASPs) tracking towards a $1,300 average for the year, and $4.5 million in milestone payments from pharmaceutical partnerships. Strategically, Adaptive is focused on several growth levers: market expansion via partnerships, notably with NeoGenomics, which is anticipated to boost testing volumes by 26-27% in years two and three; operational efficiencies through the transition to NovaSeq X instruments, projected to enhance gross margins by 5-8% within the next year and potentially double-digits longer-term; and a shift in pharma contracts to a more predictable fee-for-service model. The company projects gross margins to exceed 70% and EBITDA margins to surpass 20% for the MRD business. Key operational updates include successful Electronic Medical Record (EMR) integrations, with 33 accounts now live and 50% of order volume expected through EMR by year-end; for instance, MD Anderson's integration yielded 14% sequential quarterly order growth. Future initiatives include expanding into the community setting, where 60% of blood cancer patients are treated, launching blood-based testing advancements, and increasing ASPs towards a $1,700-$1,800 target with new gap fill pricing. Management expressed confidence in navigating potential regulatory headwinds and maintaining R&D investment, particularly in assay enhancements and the immune medicine business, which is framed as a low-cost, high-potential call option with a ring-fenced burn of $25-30 million annually.

Key Decisions for Investors

• Investors should assess the tangible impact of the NeoGenomics partnership, expected to launch its first phase in H2 2025, on testing volumes in subsequent years as a key growth catalyst.
• Monitor the progress and financial impact of the NovaSeq X instrument transition, specifically its contribution to achieving the projected 5-8% gross margin improvement and the longer-term goal of 70%+ gross margins.
• Evaluate the company's success in re-contracting with commercial payers at higher rates and transitioning pharma partnerships to a fee-for-service model, as these are critical for sustained ASP growth towards the $1,700-$1,800 target and improved revenue predictability.
• Consider the ongoing EMR integration rollout and its effect on order volume growth, particularly in community settings, alongside the managed R&D spend and developments within the immune medicine pipeline.